Transcripta Bio raised $24 million since its Series A to support IND-enabling studies across its portfolio and prepare for clinical readiness in autism spectrum disorder and facioscapulohumeral muscular dystrophy. The funding was earmarked for IND-enabling work plus continued advancement of additional programs including myotonic dystrophy and Huntington’s disease. The company’s raised capital indicates continued investor confidence in transcript-focused therapeutic mechanisms and the build-out of regulatory packages for multiple neuro indications. For biotech development teams, the multi-program IND strategy reduces single-indication dependency and may improve optionality if initial clinical signals shape longer-term platform direction. As the company moves toward trial initiation, stakeholders will watch for IND submission timelines and the selection of clinical biomarkers aligned with its mechanism of action.